Medpace Holdings, Inc. (NASDAQ:MEDP) Stock Now Rated "Hold" by Wall Street Analysts

Medpace logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts hold a cautious view: Thirteen brokerages rate Medpace “Hold” overall, with ten holds and three buys. The average 12-month price target is $642.91, below the stock’s reported opening price of $669.20.
  • Operational results remain strong: Medpace beat third-quarter earnings estimates with $4.84 EPS and approximately $716 million in revenue, up 8.5% year over year. The company also raised its 2026 EPS outlook and reported a $3.2 billion backlog.
  • Capital returns and valuation are key considerations: Medpace authorized a new $1 billion share-repurchase program, but analysts continue to flag valuation concerns and potential limited upside. Insider selling, including a roughly $30.8 million sale by the CEO, adds another factor for investors to monitor.
  • MarketBeat previews the top five stocks to own by December 1st.

Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) has been given a consensus rating of "Hold" by the thirteen brokerages that are presently covering the stock, Marketbeat.com reports. Ten analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $642.91.

A number of brokerages have recently commented on MEDP. Jefferies Financial Group restated a "hold" rating on shares of Medpace in a report on Monday, September 14th. UBS Group increased their price objective on Medpace from $673.00 to $700.00 and gave the stock a "neutral" rating in a report on Friday. Royal Bank Of Canada increased their price objective on Medpace from $484.00 to $692.00 and gave the stock an "outperform" rating in a report on Friday, July 24th. Leerink Partners set a $620.00 target price on Medpace in a research report on Thursday, July 23rd. Finally, Robert W. Baird set a $699.00 target price on Medpace in a research note on Friday.

Check Out Our Latest Analysis on Medpace

Medpace News Roundup

Here are the key news stories impacting Medpace this week:

  • Positive Sentiment: New $1 billion buyback: Medpace authorized a $1 billion repurchase program, replacing its previous authorization. The plan signals management’s confidence in cash generation and could support earnings per share by reducing the share count. Medpace Announces $1 Billion Stock Buyback Program
  • Positive Sentiment: Raised 2026 outlook: The company forecast adjusted EPS of $17.97–$18.32, above the $17.68 analyst consensus, while revenue guidance of $2.8–$2.9 billion is broadly consistent with expectations. Medpace 2026 Guidance and Buyback
  • Positive Sentiment: Q3 earnings beat: Medpace reported earnings of $4.84 per share versus the $4.45 consensus estimate, with revenue of approximately $716 million and year-over-year revenue growth of 8.5%. Margin expansion helped drive the earnings outperformance. Medpace Q3 Earnings Beat
  • Positive Sentiment: Demand remains healthy: Net new business awards reached $873 million in the third quarter, and ending backlog increased 5.6% year over year to $3.2 billion, supporting future revenue visibility. Medpace Long-Term Investor Takeaways
  • Neutral Sentiment: Analyst targets moved higher but ratings remain cautious: TD Cowen raised its target to $673 from $492 and kept a “hold” rating, while Deutsche Bank increased its target to $650 and also maintained “hold.” These revisions acknowledge the improved outlook but imply limited upside at recent trading levels. TD Cowen Medpace Rating
  • Negative Sentiment: Valuation remains a concern: Commentary following the results questioned whether MEDP is already pricing in much of its growth, with some analysis describing the shares as materially overvalued despite the earnings beat. This may explain the initial post-earnings hesitation.

Medpace Trading Up 2.3%

MEDP opened at $669.20 on Friday. The stock has a market capitalization of $18.68 billion, a P/E ratio of 37.10, a P/E/G ratio of 2.91 and a beta of 1.18. Medpace has a 12 month low of $373.00 and a 12 month high of $684.52. The firm's fifty day simple moving average is $611.66 and its 200 day simple moving average is $537.67.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its earnings results on Wednesday, October 21st. The company reported $4.84 earnings per share for the quarter, topping analysts' consensus estimates of $4.44 by $0.40. The firm had revenue of $716.00 million during the quarter, compared to analyst estimates of $714.47 million. Medpace had a net margin of 18.24% and a return on equity of 99.76%. The company's revenue for the quarter was up 8.5% compared to the same quarter last year. During the same period in the prior year, the business earned $3.86 EPS. On average, equities research analysts predict that Medpace will post 17.61 EPS for the current fiscal year.

Insider Buying and Selling at Medpace

In other news, CEO August Troendle sold 49,018 shares of Medpace stock in a transaction that occurred on Tuesday, September 22nd. The shares were sold at an average price of $628.11, for a total value of $30,788,695.98. Following the sale, the chief executive officer directly owned 433,372 shares in the company, valued at $272,205,286.92. This trade represents a 10.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, insiders have sold 336,140 shares of company stock worth $208,008,328. 20.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Novem Group increased its position in Medpace by 1.0% in the third quarter. Novem Group now owns 2,127 shares of the company's stock worth $1,328,000 after buying an additional 22 shares during the last quarter. Fifth Third Wealth Advisors LLC raised its stake in shares of Medpace by 3.2% in the third quarter. Fifth Third Wealth Advisors LLC now owns 783 shares of the company's stock valued at $489,000 after buying an additional 24 shares during the period. Balefire LLC raised its stake in shares of Medpace by 6.1% in the first quarter. Balefire LLC now owns 451 shares of the company's stock valued at $217,000 after buying an additional 26 shares during the period. Root Financial Partners LLC lifted its position in shares of Medpace by 34.1% during the 1st quarter. Root Financial Partners LLC now owns 122 shares of the company's stock valued at $59,000 after buying an additional 31 shares during the last quarter. Finally, GAMMA Investing LLC lifted its position in shares of Medpace by 2.8% during the 2nd quarter. GAMMA Investing LLC now owns 1,158 shares of the company's stock valued at $613,000 after buying an additional 32 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company's stock.

Medpace Company Profile

(Get Free Report)

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the development process, from early-stage planning and regulatory submissions through clinical trial execution, data management, analysis and reporting.

Medpace's services include Phase I through Phase IV clinical research, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.

Further Reading

Analyst Recommendations for Medpace (NASDAQ:MEDP)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Medpace Right Now?

Before you consider Medpace, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medpace wasn't on the list.

While Medpace currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines